66
Views
6
CrossRef citations to date
0
Altmetric
Review

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations

, &
Pages 205-215 | Published online: 23 Sep 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sairaj Satarker, Antriya Annie Tom, Roshitha Ann Shaji, Aaja Alosious, Mariya Luvis & Madhavan Nampoothiri. (2021) JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgraduate Medicine 133:5, pages 489-507.
Read now
Shashank Cingam, Lainey Flatow-Trujillo, Leslie A Andritsos & Cecilia Arana Yi. (2019) Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes. Journal of Blood Medicine 10, pages 381-390.
Read now

Articles from other publishers (4)

T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge & D. J. Touw. (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clinical Pharmacokinetics 62:4, pages 559-571.
Crossref
Ansab Akhtar, Jaspreet Kaur, Mei Nee Chiu & Sangeeta Pilkhwal Sah. 2023. Drug Repurposing for Emerging Infectious Diseases and Cancer. Drug Repurposing for Emerging Infectious Diseases and Cancer 395 421 .
Marissa Sjoblom, Haithem Chtioui, Montserrat Fraga, Gregoire Stalder, Francesco Grandoni & Sabine Blum. (2022) Hepatitis B reactivation during ruxolitinib treatment. Annals of Hematology 101:9, pages 2081-2086.
Crossref
Mihaila Romeo-Gabriel. (2017) A Very Rare Case of Polycythemia Vera Patient Who Developed Other Four Cancers. International Journal of Immunotherapy and Cancer Research, pages 012-014.
Crossref